Early Tests Bode Well for Bioterrorism Treatment

Add to Briefcase
Global Security Newswire Staff
Feb. 11, 2014, 7:36 a.m.

A po­ten­tial drug for use against Mar­burg vir­us has been shown in ini­tial test­ing to be safe for hu­mans, the Bo­ston Busi­ness Journ­al re­por­ted on Monday.

Phar­ma­ceut­ic­al firm Sarepta Thera­peut­ics an­nounced that when the treat­ment was giv­en in vari­ous dosage amounts over two weeks to 40 vo­lun­teers in a Phase 1 study, the drug was dis­cerned to be gen­er­ally safe, even at the largest dosage level.

Mar­burg vir­us is a hem­or­rhagic fever that can cause death in as many as nine out of 10 in­fec­ted people. Giv­en its leth­al­ity, the vir­us is a lead­ing bio­lo­gic­al-ter­ror­ism con­cern.

Sarepta Thera­peut­ics is de­vel­op­ing its Mar­burg drug un­der a De­fense De­part­ment con­tract. Ad­di­tion­al work on the med­ic­a­tion — known as AVI-7288 — de­pends on Pentagon ap­prov­al.


Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.